ORIGINAL ARTICLES 269 20 2018 Background: Limited information exists about detailed clinical characteristics and management of the small subset of Brugada syndrome (BrS) patients who had an arrhythmic event (AE). Objectives: To conduct the first nationwide survey focused on BrS patients with documented AE. Methods: Israeli electrophysiology units participated if they had treated BrS patients who had cardiac arrest (CA) (lethal/ aborted; group 1) or experienced appropriate therapy for tachyarrhythmias after prophylactic implantable cardioverter defibrillator (ICD) implantation (group 2). Results: The cohort comprised 31 patients: 25 in group 1, 6 in group 2. Group 1: 96% male, mean CA age 38 years (range 13– 84). Nine patients (36%) presented with arrhythmic storm and three had a lethal outcome; 17 (68%) had spontaneous type 1 Brugada electrocardiography (ECG). An electrophysiology study (EPS) was performed on 11 patients with inducible ventricular fibrillation (VF) in 10, which was prevented by quinidine in 9/10 patients. During follow-up (143 ± 119 months) eight patients experienced appropriate shocks, none while on quinidine. Group 2: all male, age 30–53 years; 4/6 patients had familial history of sudden death age < 50 years. Five patients had spontaneous type 1 Brugada ECG and four were asymptomatic at ICD implantation. EPS was performed in four patients with inducible VF in three. During long-term follow-up, five patients received  1 appropriate shocks, one had ATP for sustained VT (none taking quinidine). No AE recurred in patients subsequently treated with quinidine. Conclusions: CA from BrS is apparently a rare occurrence on a national scale and no AE occurred in any patient treated with quin- idine. IMAJ 2018; 20: 269–276 Brugada syndrome (BrS), cardiac arrest (CA), arrhythmic events (AE), quinidine, appropriate shocks Arrhythmic Events in Brugada Syndrome: A Nationwide Israeli Survey of the Clinical Characteristics, Treatment, and Long-Term Follow-up (ISRABRU-VF) Eran Leshem MD 1,2 , Michael Rahkovich MD 1 , Anna Mazo MD 3 , Mahmoud Suleiman MD 4 , Miri Blich MD 4 , Avishag Laish-Farkash MD 5 , Yuval Konstantino MD 6 , Rami Fogelman MD 7 , Boris Strasberg MD 8 , Michael Geist MD 9 , Israel Chetboun MD 10 , Moshe Swissa MD 11 , Michael Ilan MD 12 , Aharon Glick MD 1 , Yoav Michowitz MD 1 , Raphael Rosso MD 1 , Michael Glikson MD 3 and Bernard Belhassen MD 1 ; Israeli Working Group of Pacing and Electrophysiology 1 Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 2 Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA 3 Department of Cardiology, Sheba Medical Center, Tel Hashomer, Israel 4 Department of Cardiology, Rambam Health Care Campus, Haifa, Israel 5 Department of Cardiology, Barzilai Medical Center, Ashkelon, Israel 6 Department of Cardiology, Soroka University Medical Center, Beer Sheva, Israel 7 Heart Institute, Schneider Children's Medical Center of Israel, Petah Tikva, Israel 8 Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel 9 Department of Cardiology, Wolfson Medical Center, Holon, Israel 10 Department of Cardiology, Meir Medical Center, Kfar Saba, Israel 11 Department of Cardiology, Kaplan Medical Center, Rehovot, Israel 12 Department of Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel ABSTRACT: KEY WORDS: The abstract of this article was presented at the American Heart Association meeting, November 2016, in New Orleans, LA, USA M ore than 20 years ago, the Brugada brothers reported on eight patients with recurrent episodes of aborted sud- den death and no demonstrable heart disease that showed a peculiar electrocardiography (ECG) pattern of ST elevation in the right precordial leads [1]. Such patients represent only 6–32% of the Brugada syndrome (BrS) patients included in the largest series [2,3], and most studies on the topic have mainly dealt with patients without previous aborted cardiac arrest. To the best of our knowledge, no study has focused on the detailed clinical, ECG, electrophysiological characteristics, diagnostic workup, and long-term management of this relatively small group of patients with a ventricular arrhythmic event (AE).